GLP-1 Pipeline Tracker
This GLP-1 pipeline tracker lists about 80 GLP-1 and related drugs, from early trials to medications that are already approved. Each entry shows the drug’s class, developer, route and furthest stage. Search it, filter it, or switch to the by-stage grid. The data was checked on November 18, 2026.
GLP-1 and related drugs, by stage
Data as of November 18, 2026. Phases come from trial registrations and company announcements. Being in a trial does not mean a drug works, is safe, or will be approved. Approved and Filed can refer to a regulator outside the United States, so some approved entries are not FDA-approved.
This tracker is general information, checked on November 18, 2026. A drug's status can change after that date. Drugs still in trials are not approved, cannot be prescribed and are not available through FitRx. A place on this list does not mean a drug works, is safe or will be approved. Nothing here is medical advice.
How do you read the GLP-1 pipeline tracker?
The tracker holds one row per drug. Each row gives the drug name, its class, the developer, the route (injectable or oral) and a status. The status is the furthest stage the drug has reached for any use.
- Search. Type a drug, a brand, a company or a class. The search also reads status and route, so “Phase 3” or “oral” works too.
- Sort. Group the list by drug class or by developer, or sort it A to Z. The A to Z option applies to the list view only.
- Filter. Three buttons narrow the results to approved, oral or injectable drugs. With both Oral and Injectable pressed, you see both.
- Include Phase 1. Phase 1 drugs stay hidden until you tick this box. The line above the results says how many drugs are showing out of the total.
- Switch views. “List” is a table. “By stage” is a grid with a row for each class (or developer) and a column for each stage. Discontinued drugs are left out of the grid. A note says how many, and they stay in the list.
- Follow a name. Every drug name links to a search for that drug on ClinicalTrials.gov, the US registry of clinical studies, in a new tab.1
The colored bar above the search box shows how the whole list splits by stage. On the data date it looked like this:
| Status | Entries on November 18, 2026 |
|---|---|
| Approved | 13 |
| Filed | 2 |
| Phase 3 | 30 |
| Phase 2 | 17 |
| Phase 1 | 7 |
| Discontinued | 12 |
| Total | 81 |
Counts from the tracker’s data file as of November 18, 2026. The tool always prints its own current total.
What do the trial phases and statuses mean?
New medicines are tested in people in stages. Each stage answers a bigger question than the one before it, and a drug can stop at any of them.
| Status | In plain words |
|---|---|
| Phase 1 | The first studies in people. Groups are small, and the focus is mostly on safety and on finding a dose range. |
| Phase 2 | Larger studies that ask whether the drug does what it is meant to do, and at which doses, while side effects keep being tracked. |
| Phase 3 | The big, longer studies a company runs to confirm benefit and safety before it asks for approval. |
| Filed | The company has sent an application to a drug regulator. No decision is recorded yet. |
| Approved | A regulator has approved the drug for at least one use. |
| Discontinued | The developer has stopped the program. A few discontinued entries still show a former brand name. |
General descriptions of each stage. The tracker shows one status per drug: the furthest stage reached for any use.
The tool carries its own caution, and it is worth repeating: being in a trial does not mean a drug works, is safe or will be approved.
“Approved” does not always mean FDA-approved
Read the Approved label carefully. It records the furthest stage reached for any use, so it does not tell you that the FDA approved the drug, or that the approval is for weight loss. Thirteen entries were marked Approved on November 18, 2026. For three ingredients, this page’s fact check read the current US label: semaglutide, tirzepatide and orforglipron.2,3,4 Other approved entries print their brand names under the drug name, such as Victoza and Saxenda for liraglutide.
Six approved entries show no brand name in the tool: beinaglutide, ecnoglutide, efsubaglutide alfa, loxenatide, visepegenatide and mazdutide. We did not confirm a US approval for any of them, so do not read their status as FDA approval. The same care applies to Filed: an application may be with a regulator other than the FDA.
Even an FDA approval has limits. Ozempic and Mounjaro appear under approved ingredients, and both are approved for type 2 diabetes, not for weight loss.5,6
What “Status from company reports” means
Most statuses were checked against ClinicalTrials.gov by looking up each drug’s highest registered phase.1 For seven entries, no trial could be found in that registry under the listed name on November 18, 2026: glutazumab, visepegenatide, MWN101, ACCG-3535, MET-233i, MET-224o and RGT-075.
Those rows carry the line “Status from company reports.” It means the stage shown was not confirmed in the registry. It comes from what has been reported by or about the company, and it deserves more caution than the other rows. The name still links to a registry search, which may come back empty.
What are the drug classes in the tracker?
The tracker sorts drugs by what they act on. GLP-1 is a gut hormone, and medicines that copy it slow stomach emptying and reduce appetite.7 Newer drugs add a second or third hormone target, or take the form of a pill. The GLP-1 meaning guide covers the basics in more depth.
| Label in the tracker | In plain words | Entries | Examples from the list |
|---|---|---|---|
| GLP-1 RA | GLP-1 receptor agonists. One target: the GLP-1 receptor. | 21 | Semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity) |
| GLP-1/GIP | Dual drugs that act on the GLP-1 and GIP receptors. | 9 | Tirzepatide (Mounjaro, Zepbound), VK2735, enicepatide |
| GLP-1/glucagon | Dual drugs that act on the GLP-1 and glucagon receptors. | 6 | Survodutide, mazdutide, pemvidutide |
| GIP/GLP-1/glucagon | Triple agonists: all three receptors in one drug. | 4 | Retatrutide, efocipegtrutide |
| Amylin & combos | Drugs built around amylin, a different hormone, alone or paired with another drug. | 11 | Pramlintide (Symlin), cagrilintide, CagriSema, eloralintide |
| Oral small molecule | Pills made from small-molecule drugs. | 19 | Orforglipron (Foundayo), aleniglipron, elecoglipron |
| Other | Entries that do not fit the six groups above. | 11 | Maridebart cafraglutide, bimagrumab, brenipatide |
Classes and counts from the tracker’s data as of November 18, 2026. Brand names are the ones the tool prints under each drug.
A few notes on reading the classes:
- Dual GIP/GLP-1. Tirzepatide is the approved example. Its label describes it as a GIP and GLP-1 receptor agonist.3
- Triple agonists. Retatrutide, the best-known entry in this group, is described in its published phase 2 trial as a triple-hormone-receptor agonist.8
- Oral does not always mean small molecule. Oral semaglutide sits in the GLP-1 RA class with “Oral” as its route, because it is the same ingredient as the injection in tablet form. Orforglipron is a separate, small-molecule drug. Their labels differ in a practical way: Wegovy tablets are taken on an empty stomach with up to 4 ounces of plain water and a wait of at least 30 minutes before food, while Foundayo is taken once daily with or without food.2,4
- Code names. Early drugs often have only a code, such as VK2735. Where a drug also has a code or an earlier name, the tool shows it in brackets after the name.
- Other. This page does not describe how each drug in the last group works, because the data behind the tracker does not record it.
Which drugs in the GLP-1 pipeline are worth knowing about?
These are the entries where the November 18, 2026 fact check recorded something specific. The list is not a ranking and not a forecast.
| Drug | Developer | Class | Status | What the check found |
|---|---|---|---|---|
| Orforglipron (Foundayo) | Eli Lilly | Oral small molecule | Approved | First approved in the US in 2026, as a once-daily tablet for weight reduction and maintenance in adults with obesity, or with overweight plus at least one weight-related condition.4 |
| CagriSema | Novo Nordisk | Amylin & combos | Filed | New drug application submitted to the FDA on December 18, 2025. No FDA decision as of November 18, 2026.9 |
| Retatrutide | Eli Lilly | GIP/GLP-1/glucagon | Phase 3 | A phase 2 trial in obesity has been published. Phase 3 is the furthest registered stage.8 |
| Survodutide | Boehringer Ingelheim | GLP-1/glucagon | Phase 3 | Phase 3 is the furthest registered stage. Not filed as of the data date. |
| EloraTZP | Eli Lilly | Amylin & combos | Phase 3 | Eloralintide combined with tirzepatide. A Lilly phase 3 trial has been recruiting since October 2026. |
| BGM0504 | BrightGene | GLP-1/GIP | Phase 3 | Phase 3 trials are registered in type 2 diabetes. |
| HDM1002 | Huadong Medicine | Oral small molecule | Phase 3 | Phase 3 trials are recruiting in China. |
| VCT220 | Vcare | Oral small molecule | Phase 3 | A phase 3 obesity trial is registered as completed. |
| Ribupatide (HRS9531) | Jiangsu Hengrui | GLP-1/GIP | Filed | Listed as filed. The check did not record which regulator has the application. |
Status as of November 18, 2026, from ClinicalTrials.gov, US labels and company announcements.1 Statuses change. Follow the drug’s name in the tool for its current registry entries.
The one that already crossed the line
Orforglipron shows what the end of the pipeline looks like. In its label, adults without diabetes lost an average of 7.4%, 8.3% and 11.1% of their body weight at week 72 on the 5.5 mg, 9 mg and 17.2 mg doses, compared with 2.1% on placebo.4 Those are trial averages, not a prediction for any one person. Foundayo is not among the medications FitRx lists. It is here for context.
The ones that stopped
Twelve entries are marked Discontinued, among them danuglipron and lotiglipron from Pfizer and cotadutide from AstraZeneca. They are the plainest reminder on the page that a drug in trials is a question, not an answer. Tick “Include Phase 1” and the list grows by seven more drugs that are at the very start of that process.
What does the pipeline mean for you today?
For treatment decisions right now, very little. A drug that is still in trials has not been approved and cannot be prescribed. The way people receive an experimental drug is by taking part in a clinical trial, and the registry linked from each name is where trials are listed.1
Be wary of anyone selling a pipeline drug. The FDA says retatrutide and cagrilintide cannot be used in compounding under federal law, and that products sold “for research purposes” are illegal. Its advice is to buy only from state-licensed pharmacies.10
If you are thinking about treatment, the real choice is among medications that exist today:
- Zepbound (tirzepatide) and Wegovy (semaglutide) are FDA-approved for weight management.2,3
- Mounjaro (tirzepatide) and Ozempic (semaglutide) are FDA-approved for type 2 diabetes. They are not approved for weight loss.5,6
- Compounded semaglutide and compounded tirzepatide are a separate category. They are not FDA-approved. The FDA does not review them for safety, effectiveness or quality, and they are not generics of the brand-name drugs.10
FitRx providers can prescribe the four brand-name medications when appropriate, and a licensed provider decides whether a compounded medication is appropriate for you. Not everyone qualifies for medication.
Two sibling tools cover the practical side. The GLP-1 supply tracker shows which approved products are on the FDA shortage list, and the GLP-1 insurance checker explains how a coverage check works. For what to expect from the approved drugs, see the GLP-1 side effects guide.
Frequently asked questions
What is the GLP-1 pipeline?
It is the set of GLP-1 and related drugs that companies are developing, shown alongside the ones already approved. The tracker lists each drug with its class, developer, route and the furthest stage it has reached.
How many drugs are in the tracker?
About 80. On November 18, 2026 the list held 81 entries: 13 approved, 2 filed, 30 in Phase 3, 17 in Phase 2, 7 in Phase 1 and 12 discontinued. Phase 1 drugs are hidden until you tick the Include Phase 1 box, and the tool prints the current total above the results.
Does Approved mean FDA-approved?
Not necessarily. The status records the furthest stage a drug has reached for any use. This page confirmed current US labels for semaglutide, tirzepatide and orforglipron. Six approved entries show no brand name in the tool, and we did not confirm a US approval for them. Approved also does not mean approved for weight loss: Ozempic and Mounjaro are approved for type 2 diabetes.
Can I get retatrutide or another drug that is still in trials?
No. A drug in trials is not approved and cannot be prescribed, by FitRx or anyone else. People receive experimental drugs by taking part in a clinical trial. The FDA says retatrutide and cagrilintide cannot be used in compounding under federal law and that products sold for research purposes are illegal.
What does 'Status from company reports' mean?
It marks entries where no trial could be found on ClinicalTrials.gov under the listed name on November 18, 2026. Seven entries carry it. Their stage was not confirmed in the registry and comes from what has been reported by or about the company, so treat it with more caution.
How current is the pipeline tracker?
The data was checked on November 18, 2026, and the date is printed at the top of the tool. Trial phases, filings and approvals can change after that. Each drug name links to a ClinicalTrials.gov search where you can see its current registered trials.
References (10)
- National Library of Medicine. ClinicalTrials.gov registry of clinical studies. https://clinicaltrials.gov/
- Wegovy (semaglutide) injection and tablets. Prescribing information. Novo Nordisk; revised June 2026. https://www.novo-pi.com/wegovy.pdf
- Zepbound (tirzepatide) injection. Prescribing information. Eli Lilly and Company; revised August 2026. https://pi.lilly.com/us/zepbound-uspi.pdf
- Foundayo (orforglipron) tablets. Prescribing information. Eli Lilly and Company; revised July 2026. https://pi.lilly.com/us/foundayo-uspi.pdf
- Ozempic (semaglutide) injection. Prescribing information. Novo Nordisk; revised May 2026. https://www.novo-pi.com/ozempic.pdf
- Mounjaro (tirzepatide) injection. Prescribing information. Eli Lilly and Company; revised August 2026. https://pi.lilly.com/us/mounjaro-uspi.pdf
- Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740-756. https://pubmed.ncbi.nlm.nih.gov/29617641/
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023;389(6):514-526. https://pubmed.ncbi.nlm.nih.gov/37366315/
- Novo Nordisk. Novo Nordisk files for FDA approval of CagriSema. Press release, December 18, 2025. https://www.novonordisk-us.com/media/press-releases/novo-nordisk-cagrisema-fda-nda-submission.html
- U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Content current as of October 1, 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
Sources were opened and checked on November 18, 2026. Prices, savings programs and labels change; confirm current terms with the manufacturer, your pharmacy or your provider.
The pipeline is tomorrow. Your options are today.
FitRx pairs you with a licensed provider who reviews your health history and decides whether a GLP-1 medication that is available now is appropriate for you.
Get startedFitRx membership costs $39 in month one and $135 a month from then on. Medication is a separate charge. Not everyone qualifies.

The FitRx care team
A tracker shows what is coming. A care team works with what is here.
It is easy to wait for the next drug. A licensed provider can tell you what today’s medications can and cannot do for someone with your history. FitRx members work with a provider, a care coordinator and a coach, all online.
- U.S.-licensed providers review every intake and make every prescribing decision
- Unlimited secure messaging, plus monthly video or phone visits
- A care coordinator and a coach alongside your provider
- An insurance coordination team for brand-name GLP-1 prior authorizations
This page was written and reviewed by the FitRx care team and last updated November 18, 2026. It is general information, not personal medical advice.
GLP-1 medications our providers can prescribe
A provider decides which medication, if any, fits your health history. Compounded semaglutide and compounded tirzepatide are not FDA-approved and are not the same as the brand-name products.
More free weight loss tools
- Calorie Deficit CalculatorDaily calories to lose 1 or 2 pounds a week, and how long your goal may take.
- TDEE CalculatorHow many calories you burn in a day, activity included.
- BMR CalculatorThe calories your body uses at complete rest.
- BMI CalculatorYour body mass index and the CDC category it falls in.
- Protein CalculatorA daily protein range for losing fat, maintaining or building muscle.
- Food Noise ScoreA seven-question score for how loud thoughts about food are right now.
- Knee Relief CalculatorHow much load comes off your knees for every pound you lose.
- GLP-1 Supply TrackerFDA shortage status for GLP-1 medications, by brand and dose.
- GLP-1 Insurance CheckerHow a GLP-1 coverage check works and what happens after it.





